Lumos Pharma, Inc. (LUMO) Misses Q4 EPS by 278c

Lumos Pharma, Inc. (NASDAQ: LUMO) reported Q4 EPS of ($3.71), $2.78 worse than the analyst estimate of ($0.93). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $114.33 thousand.

For earnings history and earnings-related data on Lumos Pharma, Inc. (LUMO) click here.

You May Also Be Interested In

• Intel (INTC) PT Lowered to $92 at Mizuho
• Asana, Inc. (ASAN) Tops Q2 EPS by 1c; offers guidance
• Oxford Industries (OXM) Tops Q2 EPS by 4c; offers guidance